Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) gapped up before the market opened on Wednesday . The stock had previously closed at $1.30, but opened at $1.54. Interpace Diagnostics Group shares last traded at $1.60, with a volume of 5,373,388 shares trading hands.

A number of equities research analysts have recently issued reports on IDXG shares. Maxim Group started coverage on shares of Interpace Diagnostics Group in a report on Tuesday, August 15th. They set a “buy” rating and a $5.00 price target on the stock. ValuEngine upgraded shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) earnings per share for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%. The firm had revenue of $3.86 million for the quarter.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC acquired a new position in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned about 2.39% of Interpace Diagnostics Group at the end of the most recent reporting period. 7.41% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Interpace Diagnostics Group, Inc. (IDXG) Shares Gap Up to $1.54” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Stock Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related stocks with our FREE daily email newsletter.